NasdaqGS - Delayed Quote USD

Inozyme Pharma, Inc. (INZY)

Compare
5.54 +0.39 (+7.57%)
At close: October 18 at 4:00 PM EDT
All All Favorites Text Statistics Technicals Fibonacci Markings Lines
Loading Chart for INZY

Recent News: INZY

View More
Inozyme Pharma Announces Presentation of Interim Data from Phase 1 SEAPORT 1 Trial at the Upcoming American Society of Nephrology (ASN) Kidney Week 2024

Inozyme Pharma Announces Presentation of Interim Data from Phase 1 SEAPORT 1 Trial at the Upcoming American Society of Nephrology (ASN) Kidney Week 2024
Inozyme Pharma Announces Appointment of Biopharmaceutical Commercial Leader Erik Harris to its Board of Directors

Inozyme Pharma Announces Appointment of Biopharmaceutical Commercial Leader Erik Harris to its Board of Directors
Inozyme Pharma Presents New Data at the American Society for Bone and Mineral Research (ASBMR) 2024 Annual Meeting

Inozyme Pharma Presents New Data at the American Society for Bone and Mineral Research (ASBMR) 2024 Annual Meeting
Inozyme Pharma to Participate at the 2024 Wells Fargo Healthcare Conference

Inozyme Pharma to Participate at the 2024 Wells Fargo Healthcare Conference
Jefferies Predicts up to 270% Rally for These 2 ‘Strong Buy’ Stocks

Jefferies Predicts up to 270% Rally for These 2 ‘Strong Buy’ Stocks
Institutional owners may consider drastic measures as Inozyme Pharma, Inc.'s (NASDAQ:INZY) recent US$49m drop adds to long-term losses

Institutional owners may consider drastic measures as Inozyme Pharma, Inc.'s (NASDAQ:INZY) recent US$49m drop adds to long-term losses
Inozyme Pharma Reports Second Quarter 2024 Financial Results and Provides Business Highlights

Inozyme Pharma Reports Second Quarter 2024 Financial Results and Provides Business Highlights
Inozyme Pharma Publishes Preclinical Data Supporting INZ-701 as a Potential Therapy for a Broad Range of Serious Rare Diseases Impacting Bone Health and Blood Vessel Function

Inozyme Pharma Publishes Preclinical Data Supporting INZ-701 as a Potential Therapy for a Broad Range of Serious Rare Diseases Impacting Bone Health and Blood Vessel Function
Inozyme Pharma Announces FDA Fast Track Designation for INZ-701 in ABCC6 Deficiency

Inozyme Pharma Announces FDA Fast Track Designation for INZ-701 in ABCC6 Deficiency
Why Did Inozyme Pharma, Inc. (INZY) Get a Strong Buy Rating from Analysts?

Why Did Inozyme Pharma, Inc. (INZY) Get a Strong Buy Rating from Analysts?
Inozyme Pharma Announces Presentation and Sponsored Symposium at the 11th International Conference on Children’s Bone Health (ICCBH)

Inozyme Pharma Announces Presentation and Sponsored Symposium at the 11th International Conference on Children’s Bone Health (ICCBH)
View More

Related Tickers